Multiple myeloma (MM) is a clonal proliferation of malignant bone marrow plasma cells with
high and uniform expression of CD38 [1]. Survival has improved with autologous stem cell …

Daratumumab was the first fully human anti-CD38 monoclonal antibody (mAb) to be tested
in clinical trials, 1 demonstrating efficacy as a single agent in patients with …

Purpose Daratumumab is the first anti-CD38 monoclonal antibody of the class approved for
recurrent and refractory multiple myeloma. Grade 3 and 4 Infusion-Related Reactions (IRRs) …

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the
treatment of multiple myeloma (MM). Although recent data have demonstrated very …

Discussion Daratumumab is an IgG1κ monoclonal antibody approved by the United States
Food and Drug Administration for the treatment of multiple myeloma as both monotherapy …

Daratumumab is a first-in-class anti-CD38 moantibody approved for relapsed and refractory
multiple myeloma [1, 2] and being tested in both smoldering [3] and newly diagnosed …

Aim: Daratumumab, a CD38 monoclonal antibody, has been widely used in patients with
multiple myeloma. Although a variety of adverse events have been reported, consciousness …

Abstract Introduction: Daratumumab (Dara) is the first CD38-directed monoclonal antibody
approved for the treatment of Multiple Myeloma (MM). Dara is thought to have pleiotropic …

Introduction Daratumumab is a humanized IgG1 kappa monoclonal antibody directed
against CD38 used to treat myeloma. The recommended dose of daratumumab is 16 mg/kg …

Background Daratumumab is used in the treatment of relapsed multiple myeloma.
Daratumumab infusion-related reactions can occur with the highest incidence on the first …